Filing Details

Accession Number:
0001209191-18-034172
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-05-30 17:02:40
Reporting Period:
2018-05-30
Accepted Time:
2018-05-30 17:02:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1659323 Iterum Therapeutics Plc ITRM () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1553593 W. Michael Dunne C/o Iterum Therapeutics Plc, Blk 2
Fl. 3, Harcourt Centre, Harcourt St.
Dublin L2 2
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2018-05-30 12,730 $0.00 137,491 No 4 C Direct
Ordinary Shares Acquisiton 2018-05-30 4,050 $0.00 141,541 No 4 C Direct
Ordinary Shares Acquisiton 2018-05-30 2,917 $0.00 144,458 No 4 C Direct
Ordinary Shares Acquisiton 2018-05-30 2,000 $13.00 146,458 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Series A Preferred Shares Disposition 2018-05-30 12,730 $0.00 12,730 $0.00
Ordinary Shares Series B-1 Preferred Shares Disposition 2018-05-30 4,050 $0.00 4,050 $0.00
Ordinary Shares Series B-2 Preferred Shares Disposition 2018-05-30 2,917 $0.00 2,917 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
  2. The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
  3. The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
  4. Not applicable.